We are live on ! Find out more
TCRT icon

Alaunos Therapeutics
TCRT

27 hedge funds and large institutions have $350K invested in Alaunos Therapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more capital invested

Capital invested by funds: $158K → $350K (+$192K)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

4% more funds holding

Funds holding: 26 → 27 (+1)

1.71% more ownership

Funds ownership: 2.97% → 4.68% (+1.7%)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Holders
27
Holders Change
+1
Holders Change %
+3.85%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Two Sigma Investments
Two Sigma Investments
New York
+$60.1K
2
HF
HRT Financial
New York
+$40.7K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$29.4K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$12.8K
5
Citigroup
Citigroup
New York
+$288

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$1.78K
2
UBS Group
UBS Group
Switzerland
-$724
3
Osaic Holdings
Osaic Holdings
Arizona
-$288
4
Barclays
Barclays
United Kingdom
-$121
5
Morgan Stanley
Morgan Stanley
New York
-$120
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$97.1K +$29.4K +9,089 +43%
BlackRock
2
BlackRock
New York
$69K – – –
Geode Capital Management
3
Geode Capital Management
Massachusetts
$63.8K +$12.8K +3,945 +25%
Two Sigma Investments
4
Two Sigma Investments
New York
$60K +$60.1K +18,588 New
HF
5
HRT Financial
New York
$40K +$40.7K +12,602 New
Morgan Stanley
6
Morgan Stanley
New York
$5.32K -$120 -37 -2%
UBS Group
7
UBS Group
Switzerland
$4.23K -$724 -224 -15%
TRCT
8
Tower Research Capital (TRC)
New York
$3.49K -$1.78K -552 -34%
Osaic Holdings
9
Osaic Holdings
Arizona
$3.47K -$288 -89 -8%
CIBC Private Wealth Group
10
CIBC Private Wealth Group
Georgia
$969 – – –
Wells Fargo
11
Wells Fargo
California
$574 -$16 -5 -3%
BTI
12
Blue Trust Inc
Georgia
$436 – – –
SPIA
13
Steward Partners Investment Advisory
New York
$297 – – –
Bank of America
14
Bank of America
North Carolina
$287 – – –
Citigroup
15
Citigroup
New York
$287 +$288 +89 New
FDCDDQ
16
Federation des caisses Desjardins du Quebec
Quebec, Canada
$226 – – –
KFI
17
Key Financial Inc
Pennsylvania
$78 – – –
S
18
SignatureFD
Georgia
$74 – – –
NFSG
19
Newbridge Financial Services Group
Florida
$68 -$10 -3 -13%
NS
20
NBC Securities
Alabama
$64 – – –
AF
21
Advisornet Financial
Minnesota
$61 – – –
II
22
Inspire Investing
Idaho
$34 +$32 +10 New
SS
23
Sunbelt Securities
Texas
$32 – – –
BNP Paribas Financial Markets
24
BNP Paribas Financial Markets
France
$19 – – –
T
25
Tidemark
California
$6 +$6 +2 New
1
2

TCRT Hedge Fund Activity: Q4 2025 in Review

27 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q4 2025, worth a combined $350K — up 121% from $158K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TCRT positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 6 trimmed.

The largest buyer was Two Sigma Investments, opening a new position worth an estimated $60.1K. The largest seller was Tower Research Capital (TRC), cutting an estimated $1.78K.

  • 27 institutional investors held Alaunos Therapeutics (TCRT) as of Q4 2025, up from 26 in Q3 2025.
  • Funds reported $350K of Alaunos Therapeutics stock for Q4 2025, up 121% quarter-over-quarter.
  • 6 funds opened new Alaunos Therapeutics positions in Q4 2025 and 5 closed out, a net change of +1 holder.
  • The largest Alaunos Therapeutics buyer in Q4 2025 was Two Sigma Investments, an estimated $60.1K added.
  • The largest Alaunos Therapeutics seller in Q4 2025 was Tower Research Capital (TRC), an estimated $1.78K sold.

Based on aggregated 13F filings for Q4 2025.